Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Phage-TB

Financiado

Mycobacteriophages to treat tuberculosis - Passed station or future promise?

The emergence of drug-resistance to tuberculosis (TB) drugs poses an increasing challenge to TB control and new treatment options are urgently needed. Novel or repurposed antibiotics are still being introduced, but this pipeline w... ver más

30/04/2025

RADBOUDUMC

239K€

Presupuesto del proyecto: 239K€

Líder del proyecto

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 3 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-14

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021

I+D

Cerrada hace 3 años

0% 100%

3 Participantes

RADBOUDUMC

238.99K€ | Lider

STELLENBOSCH UNIVERSITY

SU UNIVERSITY OF STELLENBOSC...

N.D. | Participante

Proyectos interesantes

RYC2019-028015-I Phage discovery: Towards new therapies against multidrug-res... 309K€ Cerrado

PID2020-112835RA-I00 HACIA UNA TERAPIA DE FAGOS CONTRA KLEBSIELLA PNEUMONIAE RESI... 184K€ Cerrado

PID2020-117646RB-I00 EXPLORANDO NUEVAS ESTRATEGIAS EN ENFERMEDADES VIRICAS Y TUBE... 171K€ Cerrado

PID2021-123829NA-I00 EVOLUCION DIRIGIDA DEL RIBOSOMA DE MICOBACTERIAS BAJO PRESIO... 182K€ Cerrado

PID2019-104690RB-I00 DESARROLLO DE TERAPIAS ANTI-VIRULENCIA Y ESTUDIO DE LA ADAPT... 139K€ Cerrado

SAF2017-85785-R UNA APROXIMACION METAGENOMICA NOVEDOSA PARA COMBATIR LAS CRE... 194K€ Cerrado

Últimas noticias

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

01-12-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

01-12-2024: AEI En las últimas 48 horas el Organismo AEI ha otorgado 23 concesiones

Duración del proyecto: 34 meses Fecha Inicio: 2022-06-14
Fecha Fin: 2025-04-30

Presupuesto del proyecto 239K€

Descripción del proyecto The emergence of drug-resistance to tuberculosis (TB) drugs poses an increasing challenge to TB control and new treatment options are urgently needed. Novel or repurposed antibiotics are still being introduced, but this pipeline will dry out in the near future. Bacteriophages are viruses that kill bacteria. They have been used to treat infections before the introduction of antibiotics. With the emergence of drug-resistance there is renewed interest in this ancient treatment option. Clinical use of mycobacteriophages to treat TB and non-tuberculous mycobacterial (NTM) infections is still in its infancy. This project contributes to 3 areas in the development of clinically useful mycobacteriophage treatments for TB and NTM infections: - Phage discovery: From soil samples collected in the compounds of TB clinics and hospitals in Cape Town, South Africa, we will isolate mycobacteriophages using spot tests and plaque assays. DNA of newly discovered mycobacteriophages will be sequenced and during the return phase of this project I will select promising mycobacteriophages with lytic effect against TB or NTM infections, that can be used for development of phage cocktails for clinical use. - Phage inhalation method: the efficiency of phage treatment is dependent upon the phage concentration reached at the site of disease. Phages that can attack M tuberculosis have long tails which might be vulnerable to manipulation. We will optimize an inhalation method leaving the phages intact and functional. - Preparation for a clinical trial: an existing mycobacteriophage cocktail active against TB will be used for a first clinical study in humans to assess dosing, safety and efficiency. If our mycobacteriophage hunt is successful, and the translation can be made into purified and adequately dosed administration of mycobacteriophages, a virtually inexhaustible addition will be made to the therapeutic armamentarium for drug-resistant as well as drug-sensitive TB and NTM infections.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores